Skip to contentA
Aptevo Therapeutics Inc.
A
APVOAptevo Therapeutics Inc. Q1 2023 · 10-Q
Revenue—
Net Income$2.77M$2.77MN/M vs Q1 2022 EPS Diluted$17.38$17.38N/M vs Q1 2022 Operating Income-$7,756,000N/M Operating Cash Flow$4,566,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR
ended Mar 31, 2023 · filed May 11, 2023 · 41 d after period end